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Abstract
Summary Using a matched cohort design, we estimated the
mean direct attributable cost in the first year after hip frac-
ture in Ontario to be $36,929 among women and $39,479
among men. These estimates translate into an annual $282
million in direct attributable health-care costs in Ontario and
$1.1 billion in Canada.
Introduction Osteoporosis is a major public health concern
that results in substantial fracture-related morbidity and
mortality. It is well established that hip fractures are the
most devastating consequence of osteoporosis, yet the
health-care costs attributed to hip fractures in Canada have
not been thoroughly evaluated.
Methods We determined the 1- and 2-year direct attributable
costs and cost drivers associated with hip fractures among
seniors in comparison to a matched non-hip fracture cohort
using health-care administrative data from Ontario (2004–
2008). Entry into long-term care and deaths attributable to
hip fracture were also determined.
Results We successfully matched 22,418 female (mean age0
83.3 years) and 7,611 male (mean age081.3 years) hip fracture
patients. The mean attributable cost in the first year after
fracture was $36,929 (95 % CI $36,380–37,466) among wom-
en and $39,479 (95 % CI $38,311–$40,677) among men.
These estimates translate into an annual $282 million in direct
attributable health-care costs in Ontario and $1.1 billion in
Canada. Primary cost drivers were acute and post-acute insti-
tutional care. Approximately 24 % of women and 19 % of men
living in the community at the time of fracture entered a long-
term care facility, and 22 % of women and 33 % of men died
within the first year following hip fracture. Attributable costs
remained elevated into the second year ($9,017 amongwomen,
$10,347 among men) for patients who survived the first year.
Conclusions We identified significant health-care costs, en-
try into long-term care, and mortality attributed to hip frac-
tures. Results may inform health economic analyses and
policy decision-making in Canada.
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Introduction
Osteoporosis is a major public health concern that results in
substantial fracture-related morbidity and mortality [1–3]. An
estimated 30,000 hip fractures occur annually in Canada, with
incidence projected to increase with our aging population [4]. It
is well established that hip fractures are the most devastating
consequence of osteoporosis, yet the health-care costs attributed
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to hip fractures in Canada have not been thoroughly evaluated.
Prior Canadian cost-of-illness studies are outdated [5] or limited
[6, 7]. Comprehensive Canadian health-care costs attributed to
hip fractures are needed to inform health economic analyses
and guide policy decisions related to health resource allocation
[8]. The main objective of our study was to determine the mean
sex-specific direct health-care costs and outcomes attributable
to hip fractures in Ontario seniors over a 1- and 2-year period.
Methods
We used a matched cohort study design that leveraged Ontario
health-care administrative databases to determine the 1- and
2-year costs attributed to hip fractures. In Ontario, medical
claims data are available for all residents, and pharmacy claims
are available for seniors (age ≥65 years) under the Ontario Drug
Benefit (ODB) program.We identified all hip fractures between
April 1, 2004 andMarch 31, 2008 based on hospital claims. In-
hospital diagnostic codes for hip fracture have been well vali-
dated, with estimated sensitivity and positive predictive values
of 95 % [9–11]. The first date of hip fracture diagnosis defined
the index date. To allow for a minimum 1 year pre-fracture drug
exposure period, we excluded those aged less than 66 years at
index.We restricted inclusion to incident fractures by excluding
patients with any prior diagnosis of hip fracture since April
1991, the first date of available data. To maximize the likeli-
hood that hip fractures were due to underlying low bone min-
eral density attributed to osteoporosis, we excluded those with a
trauma code identified within 7 days of index, and patients with:
malignant neoplasm, Paget's disease diagnosis, or non-
osteoporosis formulations of bisphosphonates or calcitonin
within the year prior to index. Finally, we excluded non-
Ontario residents and those with death identified prior to index.
We employed an incidence density sampling strategy to
identify non-hip fracture matches. First, a random index date
was assigned to all persons in Ontario according to the sex-
specific distribution of index dates among the hip fracture
cohort. Second, the same exclusion criteria applied to the hip
fracture cohort were applied. Individuals were also excluded
from the non-hip fracture cohort if they had a hip fracture on
or within 2 years after their assigned index date. Third, all
eligible individuals in the hip fracture cohort were matched on
index date (month and fiscal year), age (±3 months), sex, and
residence status (community vs. long-term care (LTC)) to non-
hip fracture patients. Fourth, a propensity score for hip frac-
ture was calculated using logistic regression according to
collapsed aggregated diagnostic group (comorbidity score)
[12], rurality index for Ontario (population density and access
to health-care services score) [13], and income quintile. Final-
ly, hip fracture patients were matched 1:1 to non-hip fracture
individuals on the logit of the propensity score using a greedy
matching algorithm with a maximum caliper width of 0.2 and
no replacement [14]. We therefore hard matched on age, sex,
and residence status at index; all factors for which we were
interested in providing stratified results; and then propensity
score matched on comorbidity and sociodemographics that
may impact health-care resource utilization.
Health-care costing and outcomes
We used an Ontario health-care payer perspective, where only
direct costs paid by the Ontario Ministry of Health and Long-
Term Care were considered. When possible, all costs were
applied based on the year they were incurred and then inflated
and reported in 2010 Canadian dollars using the health-care
component of the Ontario consumer price index (CPI,
www.statscan.gc.ca). Detailed methods for case-costing using
administrative databases in Ontario have recently been pub-
lished [15]. In brief, acute hospitalizations, emergency depart-
ment, and same day surgery costs were calculated using the
resource intensity weight method that uses the average pro-
vincial costs per weighted case based on distinct case mix
groups [16, 17]. Costing in complex continuing care was
based on distinct resource utilization groups, case mix index,
and number of days in care [18]. Physician service costs and
prescription drug costs were based on the total amount paid to
the physician/pharmacy from the Ministry of Health. Costs
related to length of stay in rehabilitation were based on the
rehabilitation patient group case mix classification and
weighting system for Ontario [19–21]. Costs for home care
were determined by applying an average cost per service (or
hour) [22]. LTC costs were calculated based on the average
cost per day and length of stay. In addition to health-care costs,
we assessed the number of individuals who died, entered LTC,
and experienced a second hip fracture.
Statistical analysis
Cohort characteristics were summarized using means and
proportions. Balance between matched cohorts was assessed
using standardized difference, where values <0.1 indicate
balance [23]. Cohorts were compared for each matched
variable as well as on osteoporosis screening (DXA test),
diagnosis, treatment, and fractures (humerus/radius/ulna,
vertebral, or others) within 365 days prior to index.
Health resource utilization and outcomes were compared
between matched cohorts using the McNemar chi-square test
for categorical variables and the paired t test for continuous
variables. Total costs were determined by summation of each
costing component and presented as the mean cost over the
first and second year. Attributable hip fracture costs were
determined by subtracting costs in the non-hip fracture cohort
from the costs in the matched hip fracture cohort [24]. Variance
estimation (95%CI) was determined using bootstrapping with
replacement [24]. All costs were stratified by resource type
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(acute hospitalization, same day surgery, emergency depart-
ment, complex continuing care, rehabilitation, LTC, home
care, physician services, prescriptions for osteoporosis, and
pain medications), sex, age group (66–69, 70–74, 75–79, 80–
84, 85–89, 90+), and residence status (community or LTC) at
baseline. In an effort to determine costs attributed to death from
hip fracture, we further evaluated costs among concordant
pairs who survived or died within 1- and 2-years of follow-
up. One-year attributable hip fracture costs in Canada were
estimated by multiplying sex-specific attributable mean costs
in Ontario by 30,000—the total number of hip fractures esti-
mated to occur annually in Canada [4, 25].
Results
We identified 36,253 hip fracture patients, of which 31,064
(86 %) were eligible. Exclusions were primarily as a result of
prior hip fracture (56 % females and 30 % males) and a diag-
nosis of malignant neoplasm (34 % females, 52 % males),
Appendix Fig. 1. After applying exclusion criteria and identify-
ing suitable non-hip fracture matches, the final cohort included
30,029 matched pairs (22,418 females, 7,611 males). Mean age
at hip fracture was 83.3 years (SD07.1) for females and
81.3 years (SD07.1) for males (Table 1). About one-fifth
(21 % females, 18 % males) of patients resided in LTC at the
time of fracture. The sex-specific matched fracture and non-hip
fracture cohorts were well balanced on matched variables, as
well as on prior osteoporosis diagnosis. However, more hip
fracture patients had been dispensed an osteoporosis medication
or incurred a non-hip fracture in the year prior to fracture.
Outcomes and resource utilization
With the exception of same day surgery, more individuals in the
fracture cohort than the non-hip fracture cohort utilized health-
care resources (Table 2). Approximately 30 % of hip fracture
patients required rehabilitation, 18 % required complex con-
tinuing care, and over 65 % received home care services.
Physician services were utilized by more than 94 % of individ-
uals in both cohorts; however, hip fracture patients received
nearly twice as many individual services: 2,468,744 vs.
1,336,071 (women) and 852,834 vs. 480,829 (men). Of
patients residing in the community at the time of hip fracture,
19 % (men) to 24 % (women) entered a LTC facility within a
year of hip fracture. Less than 22% ofmen and 50% ofwomen
received osteoporosis medication after hip fracture. More men
(33 %) than women (22 %) died within the year after hip
fracture, resulting in an absolute increase in death of 23 %
among men and 13 % among women in the first year. Risk of
death increased with age and LTC residence at baseline.
During the 2-year follow-up period, 3 % of females and
2 % of males incurred a subsequent hip fracture. Health
services utilization in the second year remained elevated in
the hip fracture cohort. Among those who survived the first
year, a marginal increase in death of 3 % for women and 6 %
for men in the hip fracture cohort was observed in the
second year (Appendix Table 5).
Health-related costs
The total direct 1-year health-care cost of hip fracture ranged
from $52,232 (females) to $54,289 (males) with mean 1-year
attributable cost of $36,929 for females and $39,479 for males
(Table 3). Applying these sex-specific mean costs to the esti-
mated 30,000 hip fractures that occur annually in Canada (75%
among women), the direct attributable health-care cost of hip
fracture is approximately $1.1 billion per year in Canada. Acute
hospitalizations accounted for the largest component of attrib-
utable hip fracture costs, with 38 %–41 % of the cost resulting
from the index hospitalization. Other primary drivers of first
year costs included complex continuing care, rehabilitation, and
physician services. Attributable costs generally decreased with
age, reflecting both increased total costs with age in the non-hip
fracture cohort and increased risk of death after hip fracture.
Costs among the hip fracture cohort remained elevated into the
second year post fracture, with a mean attributable cost of
$4,599 for females and $3,083 for males (Appendix Table 6).
Mean total and attributable hip fracture costs stratified by
residence status, number of hip fractures, and survival status
are summarized in Table 4. Attributable costs were greatest
among individuals residing in the community at baseline, those
incurring a second hip fracture, and those who survived the
study period. Among matched survivors, the mean 1-year
attributable costs were $41,149 in females and $45,742 in
males. First-year attributable costs among those who died in
the first year were $10,935 among women and $14,451 among
men. Among individuals who survived the first year, second-
year attributable costs were $9,017 for women and $10,347 for
men. LTC residence, acute hospitalizations, and home care
accounted for the greatest proportion of the latter costs.
Across the four fiscal years evaluated, the total cumula-
tive first year attributable cost of hip fractures in Ontario
was estimated at $282.1 million (females0$206.9 million,
males0$75.1 million). The total cumulative attributable cost
in the second year was $64.5 million in Ontario.
Discussion
Our results emphasize the major health and economic bur-
den of hip fractures on the Canadian health-care system. The
1 year direct attributable health-care system cost of hip
fracture was $282.1 million in Ontario, with survivors cost-
ing an additional $64.5 million in the second year post-
fracture. Based on these estimates and reports that indicate
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approximately 30,000 hip fractures annually in Canada [4,
25], the direct attributable health-care cost of hip fracture is
approximately $1.1 billion per year in Canada.
Three prior studies have evaluated the longitudinal cost
of hip fractures from a Canadian perspective [5–7]. The first
study estimated the mean total 1-year direct cost of hip
fracture at $27,527 in 1997 dollars (CPI adjusted to
$42,942 in 2010 dollars) [5], much lower than our total
direct costs ($52,232 to 54,289, 2010 dollars). Differences
in cost estimates likely reflect changes in health-care system
costs over time as well as variations in study designs.
Primarily, authors relied on patient chart review and inter-
views to estimate resource utilization among hip fracture
patients in a single Ontario region, with our analysis providing
a more comprehensive estimate based on actual resource
utilization for hip fractures across Ontario. Although total
costs are useful, attributable costs provide greater clinical
implication for health policy decision-making as it adjusts
for costs of typical health-care resource use among similar,
non-hip fracture individuals [24, 26]. The 1-year direct cost of
hip fracture among women from three regions in Québec was
estimated to be $46,664 in 2009 dollars ($47,804 in 2010
dollars). This estimate is closer to our total direct mean cost
estimate ($52,232 among women), yet is limited by not includ-
ing a control group to permit the identification of attributable
costs of hip fractures, or considering men [7]. Fracture costs
were recently estimated using provincial data from Manitoba
[6]. Although this study was comprehensive by estimating the

















Acute hospitalizations 100 19.1 80.9* 100 22.6 77.4*
Same day surgeries 9.5 12.8 −3.3* 14.1 19.4 −5.3*
Emergency visits 86.5 36.6 49.9* 86.3 38.1 48.2*
Complex continuing care 17.7 1.4 16.3* 17.8 1.4 16.4*
Rehabilitation 32.8 1.4 31.4* 31.9 1.1 30.8*
Long-term care 38.0 24.6 13.4* 30.0 20.1 9.9*
Community at index 23.6 4.6 19.0* 19.0 3.4 15.6*
Home care 69.5 26.3 43.2* 66.1 21.5 44.6*
Physician services 100 94.5 5.5* 100 94.7 5.3*
DXA test 4.3 5.2 −0.9* 2.5 1.9 0.6*
Prescriptions 92.4 93.2 −0.8* 85.3 92.1 −6.8*
Osteoporosis treatment 43.7 27.8 15.9* 21.7 6.6 15.1*
Opioids 53.7 28.2 25.5* 48.7 24.9 23.8*
NSAIDs 18.9 23.4 −4.5* 17.2 22.6 −5.4*
Health outcomes
Second hip fracture 1.2 0 1.2* 0.8 0 0.8*
Death (overall) 22.2 9.3 12.9* 33.4 10.8 22.6*
Age group
66–69 9.3 1.7 7.6* 13.2 1.9 11.3*
70–74 11.7 2.4 9.3* 19.2 3.9 15.3*
75–79 14.1 4.4 9.7* 26.9 6.8 20.1*
80–84 18.9 7.3 11.6* 33.2 10.1 23.1*
85–89 25.1 11.1 14.0* 43.3 16.3 27.0*
90+ 35.9 17.7 18.2* 51.6 20.5 31.1*
LTC at index 37.0 22.6 14.4* 53.6 28.9 24.7*
Community at index 18.2 5.7 12.5* 29.1 6.9 22.2*
Attributable percentage of hip fracture patients − percentage of non-hip fracture patients, LTC long-term care, NSAID nonsteroidal anti-
inflammatory drug
*p<0.05 (significant at this level)
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median attributable costs of several types of fracture (hip, wrist,
humerus, and a group of other fractures), it was limited in its
ability to incorporate costs associated with specific home care,
rehabilitation, or emergency department services. Authors esti-
mated the 1-year median direct attributable costs by subtracting
pre-fracture costs from post-fracture costs with attributable hip
fracture costs estimates of $20,129 in women and $19,330 in
men (2006 dollars) after adjustment [24], which are substan-
tially lower than our mean estimates of $36,929 in women and
$39,479 in men. Our study reports mean attributable costs, the
metric used in cost-effectiveness analyses [27, 28], whereas the
Manitoba study provides median costs. Collectively, these
methodological variations may explain cost differences be-
tween our studies.
Our study is also unique by providing attributable
costs associated with residence in LTC and survival, as
well as costs and health-care utilization in the second
year. Indeed, we found that attributable hip fracture costs
were higher for individuals living in the community at
the time of fracture—related to the large proportion of
community-dwelling seniors that relocate to LTC post-hip
fracture. Our results may thus be readily applied to
inform cost-effectiveness analyses based on interventions
among residents in long-term care and those residing in
the community.
Costing analyses are often difficult to generalize between
countries due to differences in actual costs, health-care
systems, and treatment patterns. However, the substantial
costs, low rates of post-fracture screening and treatment, and
mortality subsequent to hip fractures reported in our study
are comparable to other countries [29–31]. A recent system-
atic review of US health-care costs identified the US hip
fracture hospitalization unit cost to range from $8,358 to
32,195 US dollars and medical costs to range between
$15,294 and 71,272 US dollars [29]. Of greatest clinical
concern is the loss of independence and mortality risk fol-
lowing hip fracture and low treatment rates. Our findings are
consistent with prior estimates [1, 31–34] and emphasize the
urgent need to better manage osteoporosis and develop
targeted interventions to reduce hip fracture risk. We found
that only 10 % (men) to 32 % (women) of patients filled an
osteoporosis treatment prior to fracture, and this increased
only to 22 % of men and 44 % of women within the year
after hip fracture. The Ontario Ministry of Health and Long-
Term Care funded a post-fracture care strategy that started to
screen patients in fracture clinics in 2007 and an interven-
tion among small community hospitals in 2008—both aim
to improve post-fracture osteoporosis management [35, 36].
Post-fracture testing and treatment rates may thus have
improved in recent years, and our results may inform cost-
Table 3 Mean total direct health-care costs (2010 Canadian dollars) in first year after index date in the hip fracture and non-hip fracture cohorts, by
sex









Attributable (95 % CI) %
Acute hospitalizations 21,502 2,710 18,792 (18,471, 19,119) 51 24,915 3,626 21,289 (20,573, 21,957) 54
Index hospitalization 14,210 – 14,210 (14,021, 14,400) 39 16,158 – 16,158 (15,711, 16,605) 41
Same day surgeries 120 153 −33 (−44, −22) 0 178 236 −58 (−83, −37) 0
Emergency visits 769 286 483 (472, 495) 1 831 322 509 (486, 532) 1
Complex continuing care 5,996 408 5,588 (5,323, 6,872) 15 6,934 466 6,468 (5,859, 7,037) 16
Rehabilitation 5,518 268 5,250 (5,107, 5,396) 14 5,700 247 5,453 (5,184, 5,730) 14
Long-term care 9,419 6,949 2,470 (2,315, 2,654) 7 6,746 5,494 1,252 (956, 1,521) 3
Home care 2,132 997 1,135 (1,069, 1,149) 3 2,050 705 1,345 (1,235, 1,458) 4
Physician services 4,525 1,422 3,103 (3,065, 3,142) 9 4,905 1,640 3,265 (3,190, 3,353) 8
Prescription medications 2,251 2,111 140 (102, 177) 0 2,030 2,073 −43 (−113, 34) 0
Total mean cost/year 52,232 15,303 36,929 (36,380, 37,466) 100 54,289 14,810 39,479 (38,331, 40,677) 100
Age group
66–69 45,886 7,020 38,866 (35,910, 41,608) 46,551 6,699 39,852 (35,439, 44,764)
70–74 47,250 9,373 37,877 (36,063, 39,850) 52,446 9,568 42,878 (39,501, 46,073)
75–79 50,924 12,437 38,487 (37,222, 38,489) 56,927 14,549 42,378 (39,472, 45,240)
80–84 52,863 14,859 38,004 (36,939, 39,111) 55,739 16,186 39,553 (37,312, 41,752)
85–89 54,542 17508 37,034 (36,023, 38,131) 54,456 16,647 37,809 (35,510, 40,251)
90+ 52,810 19,396 33,414 (32,119, 34,693) 52,405 18,433 33,972 (31,164, 36,869)
Attributable mean cost hip fracture cohort − mean cost non-hip fracture cohort, CI confidence interval
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effectiveness analyses of interventions to reduce hip fracture
risk.We identified that 24% of women and 19% ofmen living
in the community at the time of fracture entered a long-term
care facility, and 22% of women and 33 % of men died within
the first year following hip fracture. Our results also identify
that death remained elevated into the second year post-fracture,
a finding previously been shown to persist for up to 5 to
10 years post-fracture [3, 32, 37]. However, the underlying
contribution of fracture vs. underlying frailty towards mortality
post-hip fracture remains uncertain. While there is a growing
body of literature evaluating sex-related differences in osteo-
porosis [38, 39], understanding sex differences in mortality
following hip fractures warrants further study.
There are study limitations worth noting. First, although our
hip and non-hip fracture cohorts were well matched, matching
could only be achieved based on observed variables. Unmea-
sured factors such as frailty could be associated with hip
fracture risk and subsequent health-care utilization and mortal-
ity. We therefore may have overestimated the attributable costs
associated with hip fracture by insufficient matching on under-
lying frailty. Second, while there is a significant value in
health-care utilization data to estimate health-care resource
use, it is possible that some hip fractures or costs were not
identified. Nonetheless, hip fracture hospitalization codes are
one of the most reliable hospital diagnoses [9], and overall
database validity has been thoroughly described in literature
[15]. Prescription drug costs may also be underestimated as
drugs dispensed in hospital are not captured in the ODB
pharmacy claims; however, they are accounted for in the cost
per weighted hospital case and thus included in the hospitali-
zation cost. We thus anticipate that our study is comprehensive
and provides a good estimate of the direct health-care costs
attributed to hip fractures. However, we also acknowledge that
by using a health-care payer perspective, patient costs, such as
prescription co-pay and patient-specific costs for LTC accom-
modation were not considered.
Major study strengths include our comprehensivelymatched
non-hip fracture cohort and analyses reported by age, sex, and
residence status. We identified significant health-care costs,
entry into LTC, and mortality attributed to hip fractures. As
our population ages, the number of hip fractures is estimated to
increase [4]. Unless resources are allocated toward the preven-
tion and efficient management of hip fractures, these fractures
will increasingly become a major burden to our health-care
system. Our results provide a framework to inform future
research into the health and economic impact of osteoporotic
fractures, and data can be readily used in cost-effectiveness
analyses. Our results are particularly timely as new osteoporosis
treatments enter the market and we examine interventions to
reduce hip fracture risk among seniors.
Table 4 Total and attributable direct health-care costs (2010 Canadian dollars) of hip fracture stratified by residence at baseline, second hip
fracture, and survival
















($) (95 % CI)
Residence status (cost year 1)
LTC at baseline 100 48,723 37,510 11,213 (10,469, 11,986) 100 46,931 37,758 9,174 (7,365, 10,911)
Community at baseline 100 53,187 9,258 43,930 (43,292, 44,560) 100 55,878 9,853 46,025 (44,821, 47,313)
LTC at baseline—
survived year 1b
78.4 59,015 41,474 17,541 (16,803, 18,218) 73.7 63,159 42,895 20,263(18,163, 22,577)
Community baseline—
survived year 1b
94.8 53,386 8,139 45,247 (44,548, 45,955) 93.9 56,750 8,184 48,566 (47,118, 50,174)
Second hip fracture
Second hip fracture in year 1
(cost year 1)
NA 85,614 14,992 70,621 (65,777, 76,063) NA 87,726 14,088 73,638 (60,853, 86,245)
Second hip fracture in year 2
(cost year 2)
NA 52,912 13,018 39,895 (36,459, 43,374) NA 63,939 11,481 52,458 (44,611, 60,923)
Survival statusb
Survived year 1 (cost year 1) 96.3 54,218 13,069 41,149 (40,489, 41,774) 91.4 57,390 11,648 45,742 (44,257, 47,098)
Survived year 1 (cost year 2) 96.3 22,983 13,966 9,017 (8,578, 9,471) 91.4 22,909 12,563 10,347 (9,417, 11,275)
Survived year 2 (cost year 2) 80.1 22,019 12,467 9,552 (9,141, 10,004) 71.7 21,032 10,524 10,507 (9,514, 11,451)
Died year 1 (cost year 1) 13.8 34,873 23,938 10,935 (8,347, 13,364) 15.2 40,216 25,765 14,451 (10,062, 18,826)
Died year 2 (cost year 2) 10.5 23,696 23,470 226 (−4,297, 4,939) 11.2 26,806 26,336 469 (−5,073, 6,383)
Died year 2 (cost year 1) 10.5 70,601 32,134 38,466 (36,376, 39,487) 11.2 72,568 26,336 46,232 (38,285, 47,503)
Attributable mean cost hip fracture cohort − mean cost non-hip fracture cohort, CI confidence interval, LTC long-term care, NA not applicable
a Percentage of hip fracture patients with a matched concordant pair
b Calculated only among concordant pairs who both survived or died in the given year
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Appendix
A. Hip Fracture Cohort B. Non-Hip Fracture Cohort
Hip Fracture Cohort eligible for potential 
match to non-hip fracture cohort 
N = 23,009 (86.3%) females 
N = 8,055 (83.9%) males 
A. All individuals in RPDB between April 
2004-March 2008, Aged 66+ by Mar08 
N = 1,168,713 females  
N = 940,448 males 
B. Hip Fracture Diagnosis (Apr04-Mar08) 
N = 26,648 females  
N = 9,605 males 
Non-Hip Fracture Cohort eligible for 
potential match to hip fracture cohort 
N = 869,041 (74.4%) males 
N = 681,173 (72.4%) females 
A. All individuals in RPDB between April 
2004-March 2008, Aged 66+ by Mar08 
N = 1,168,713 females  
N = 940,448 males 
Ineligible, N = 558,947 (26.5%)  
N = 299,672 (25.6%) females, 259,275 (27.6%) males 
Age <66 years at index 
N = 120,262 (40.1%) females, 114,178 (44.0%) males 
Prior Hip Fracture 
N = 44,891 (15.0%) females, 14,068 (5.4%) males 
Trauma Code (+/-7d of index)  
N = 32 (0%) females, 46 (0%) males 
Non-Osteoporosis dispensing of a 
bisphosphonate/calcitonin 
N = 1331 (0.4%) females, 387 (0.1%) males 
Malignant Neoplasm  
N = 44,030 (14.7%) females, 51,558 (19.9%) males 
Paget’s Disease  
N = 852 (0.3%) females, 698 (0.3%) males 
Non-Ontario Residents 
N =89,188 (29.8%) females, 82,115 (31.7%) males 
Death coded prior to index  
N = 69,221 (23.1%) females, 63,597 (24.5%) males 
Hip fracture within 2-years of follow-up 
N = 13,768 (4.6%) females, 5,158 (2.0%) males 
Final Hip Fracture Cohort 
N = 22,418 females 
N = 7,611 males 
Unavailable matching variables or match 
N = 591 (2.6%) females, 444 (5.5%) males 
Final Non-Hip Fracture Cohort 
N = 22,418 females 
N = 7,611 males 
Unavailable matching variables or match 
N = 837,139 (3.7%) females, 664,564 (2.4%) males 
Ineligible, N = 5189 (14.3%)  
N = 3,639 (13.7%) females, 1,550 (16.1%) males 
Age <66 years at index 
N = 341 (9.4%) females, 261 (16.8%) males 
Prior Hip Fracture 
N = 2,052 (56.4%) females, 459 (29.6%) males 
Trauma Code (+/-7d of index) 
N = 26 (0.7%) females, 52 (3.3%) males 
Non-Osteoporosis dispensing of a 
bisphosphonate/calcitonin 
N = 12 (0.3%) females, 81 (5.2%) males 
Malignant Neoplasm 
N = 1,238 (34%) females, 809 (52%) males 
Paget’s Disease 
N = 27 (0.7%) females, 19 (1.2%) males 
Non-Ontario Residents 
N = 12 (0.3%) females, 3 (0.2%) males 
Death coded prior to index 
N = 3 (0.1%) females, 0 (0%) males 
Fig. 1 Study flow diagram for hip and non-hip fracture cohort inclusion. RPDB means registered persons database. Exclusions are not mutually
exclusive and thus will not add to 100 %
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Acute hospitalizations 19.3 16.9 2.4* 20.7 19.5 1.2
Same day surgeries 8.6 11.5 −2.9* 11.2 17.2 −6.0*
Emergency visits 32.1 36.6 −4.5 30.6 33.8 −3.2*
Complex continuing care 1.5 1.0 0.5* 2.1 1.1 0.6*
Rehabilitation 1.8 1.1 0.7* 1.5 0.9 0*
Long-term care 32.1 22.2 9.9* 22.2 16.9 5.3*
Community at index 23.8 7.3 16.5* 17.0 5.3 11.7*
Home care 29.1 23.6 5.5* 24.5 19.5 5.0*
Physician services 76.5 85.0 −8.5* 65.2 83.7 −18.5*
DXA test 6.6 8.8 −2.2* 3.3 1.9 1.4*
Prescriptions 75.6 84.0 −8.4* 63 81.6 −18.6*
Osteoporosis treatment 37.0 26.1 10.9* 16.6 6.2 10.4*
Opioids 27.4 24.7 2.7* 22.7 21.7 1.0
NSAIDs 13.8 19.5 −5.7* 11.7 18.7 −7.0*
Health outcomes
Second hip fracture 1.7 0 1.7 1.4 0 1.4*
Death (overall) 9.1 8.3 0.8* 11.3 9.4 1.9*
Age group
66–69 4.8 1.7 3.1* 7.8 1.7 6.1*
70–74 5.6 2.7 2.9* 8.4 3.9 4.5*
75–79 7.7 4.9 2.8* 10.2 6.7 3.5*
80–84 8.2 6.4 1.8* 11.7 10.2 1.5
85–89 10.2 9.8 0.4* 12.6 12.8 −0.2
90+ 12.5 14.9 −2.4* 14.4 15.7 −1.3
LTC at index 12.4 17.2 −4.8* 14.2 19.7 −5.5*
Community at index 8.2 5.8 2.4* 10.7 7.1 3.6*
Attributable percentage of hip fracture patients − percentage of non-hip fracture patients, LTC long-term care, NSAID nonsteroidal anti-
inflammatory drug
*p<0.05 (significant at this level)
Table 6 Mean total and attributable direct health-care costs (2010 Canadian dollars) in second year after index date among in the hip fracture and
non-hip fracture cohorts, by sex











Attributable (95 % CI) %
Acute hospitalizations 2,988 2,414 574 (388, 771) 12 3,889 3,104 785 (347, 1247) 25
Same day surgeries 107 141 −33 (−44, −23) 0 133 211 −78 (−99, −58) 0
Emergency visits 266 255 11 (0, 21) 0 292 285 7 (−14, 28) 0
Complex continuing care 372 197 174 (104, 244) 4 532 174 358 (229, 485) 23
Rehabilitation 343 246 97 (37, 151) 2 297 177 120 (30, 209) 4
Long-term care 9,569 6,356 3,213 (2,984, 3,435) 70 6,202 4,627 1,575 (1,188, 1,877) 51
Home care 1,284 919 364 (302, 429) 8 1,180 649 531 (427, 641) 17
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Attributable (95% CI) %
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Attributable mean cost hip fracture cohort − mean cost non-hip fracture cohort, CI confidence interval
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